• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 26th March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

This presentation to the Australian Society for Antimicrobials (ASA) meeting in Melbourne, on 27th February 2020 draws on OHE research, funded by the Wellcome Trust, on adapting HTA methods and contracting for new antibiotics. It analyses UK (NICE and NHSE)…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This presentation to the Australian Society for Antimicrobials (ASA) meeting in Melbourne, on 27th February 2020 draws on OHE research, funded by the Wellcome Trust, on adapting HTA methods and contracting for new antibiotics. It analyses UK (NICE and NHSE) plans to introduce a subscription model (delinking use of new antibiotics from payments for making the products available) and suggests that Australia could also pilot such an approach.

This presentation to the Australian Society for Antimicrobials (ASA) meeting in Melbourne on 27th February 2020, draws on OHE research funded by the Wellcome Trust, on adapting HTA methods and contracting for new antibiotics. It analyses UK (NICE and NHSE) plans to introduce a subscription model (delinking use of new antibiotics from payments for making the products available) and suggests that Australia could also pilot such an approach.

Antibiotics available today are becoming obsolete at a fast pace, and industry development pipelines of antibiotics are weak. Prices for new antibiotics are low (because they do not reflect the value of these products to society) and sales volumes are also low (because infectious disease clinicians want to conserve new drugs for use in multi-drug resistant patients to preserve the effectiveness of these drugs for as long as possible). As a result, revenues are too low to justify R&D investment.

Various initiatives, for example CARB-X and the G20 AMR R&D hub, are seeking to increase R&D, notably through the use of ‘push’ incentives. However, without an effective market (a ‘pull’ incentive) there will not be enough new antibiotics.

Solving the value assessment challenge.

Value assessment of new drugs is typically based around RCTs to show clinical superiority against a comparator treatment. This is a problem for new antibiotics because estimates of effectiveness in patients to be treated are typically based on non-superiority trials and non-clinical data (such as PK/PD and in-vitro microbiological data) which are typically not accepted by HTA agencies. Moreover, a considerable part of antibiotic value arises from externalities (benefits and costs to the non-treated individuals) which are not measured in RCTs. The typically ‘not included’ elements of the value of new antibiotics appear to be much larger than the immediate health gain to the patient.

We need HTA bodies to (i) accept new approaches to measuring effectiveness and (ii) to value these ‘not included’ elements, beginning with those, such as the value of reduced transmission, that have the greatest impact on overall value, and for which it is possible to generate evidence. Research has been done but more is needed to improve measurement of these effects. Expert elicitation will be crucial to get estimates to inform assessment of these ‘not included’ elements of value.

Solving the contractual challenge

Most pricing & reimbursement arrangements agree on a price per pill. This is a problem for new antibiotics because stewardship arrangements limit use of the drug during the period of patent protection to optimise long term social value.  These low volumes will not provide a return on investment for developers. Several proposals have been put forward in Europe and the USA for delinking payments for new antibiotics from the volumes used. The UK proposals by NICE and NHS England have the overall objective to put in place a subscription model for purchasing antibiotics and ensure that learnings are shared with the international community.  There are three elements:

  1. Selection of candidate drugs: with a pilot planned of 2 drugs, one new and one existing, with separate procurement lots, and the use of procurement through ‘competitive dialogue’.
  2. Valuation: with use of modified NICE HTA processes including use of pre-clinical data (e.g. PK/PD data) to estimate health gain, and expert opinion to estimate cost savings and AMR specific elements of diversity; transmission; enablement; spectrum benefits; and the insurance benefits of the new antibiotic.
  3. Contracting: which is expected to be a fully delinked subscription model, with pre-agreed payments linked to delivery of data and of product when needed. The period of the contract is not yet specified, but it could be 5 years, renewable with new data.

The UK AMR 5 year vision was launched in January 2019; the pilot launched in July 2019; a stakeholder update was given in Nov 2019; draft documents are expected in March /April 2020.

Like the UK, Australia has high quality HTA valuation expertise for new vaccines and for new drugs. The experience of its ‘Netflix’ style subscription model for Hep.C DAA drugs indicated to rest of the world Australia’s ability to undertake innovative contracting arrangements. It has the skills to introduce a subscription model along the broad lines of the UK approach with three elements:

  1. Selection process for candidates (The UK is planning 2 products initially)
  2. Valuation process – recognition that expert opinion will inform conventional HTA approaches, with the need for ad hoc approaches whilst more detailed approaches are developed
  3. Contracting – multi-year ‘delinked’ contract with an obligation to supply in line with clinical protocols that enforce appropriate stewardship of existing and new antibiotics.

There is the challenge of a Federal scheme displacing State funding for hospital drugs. This is comparable in some ways to the UK challenge of replacing decentralised hospital contracts finances with a national subscription contract.

The more experience the international community develops in contracting for new antibiotics, the sooner we will learn how to get this right.

Please see slides below:

A short four-page summary of the OHE research project is available to download as a PDF. A podcast based on the presentation can be listened to here

Disclosures:

The research on which this presentation was based was funded by the Wellcome Trust.

The trip to Australia to speak at Antibiotics 2020 was funded by MSD (Merck & Co.)

Related Research:

Ferraro, J., Towse, A. and Mestre-Ferrandiz, J., 2017. Incentives for New Drugs to Tackle Anti-Microbial Resistance. OHE Briefing. London: Office of Health Economics. RePEc.

Karlsberg Schaffer, S., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J., Masterson, R. and Fischer, A., 2017. Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions. OHE Briefing. London: Office of Health Economics. RePEc.

Towse, A., Hoyle, C., Goodall, J., Hirsch, M., Mestre-Ferrandiz, J., Rex J. 2017. Time for a Change in How New Antibiotics are Reimbursed: Development of an Insurance Framework for Funding New Antibiotics based on a Policy of Risk Mitigation. Health Policy http://dx.doi.org/10.1016/j.healthpol.2017.07.011

 

 

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation
  • Presentations

Related News

  • News
  • March 2020

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Read more
  • News
  • January 2020

Funding Challenges in the Malaysian Health Care System

Read more
  • News
  • January 2020

OHE at HESG Winter 2020

Read more
  • News
  • December 2019

OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!